14-3-3η: A novel biomarker platform for rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S35-S39

  Maksymowych, Walter P ^a   Marotta, Anthony ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Augurex Life Sciences Corp   (Canada)

Author keywords

14 3 3 biomarker platform; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; PROTEIN 14 3 3; PROTEIN 14 3 3 ETA; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ANTIBODY BLOOD LEVEL; ARTICLE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX;

14-3-3 PROTEINS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RHEUMATOID FACTOR; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84922395363     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. DEMORUELLE MK, DEANE KD: Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr Rheumatol Rep 2012; 14: 472-80.
2. BOS WH, DIJKMANS BA, BOERS M, van de STADT RJ, van SCHAARDENBURG D: Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis 2010; 69: 571-4.
3. BOS WH, WOLBINK GJ, BOERS M et al.: Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2010; 69: 490-4.
4. NIELEN MM, van SCHAARDENBURG D, REESINK HW et al.: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-6.
5. SHI J, van de STADT LA, LEVARHT EW et al.: Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 2013; 65: 911-5.
6. van de STADT LA, BOS WH, MEURSINGE REYNDERS M et al.: The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis Res Ther 2010; 12: R98.
7. MAKSYMOWYCH WP, LANDEWé R, TAK PP et al.: Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009; 36: 1785-91.
8. de ROOY DP, van der LINDEN MP, KNEVEL R, HUIZINGA TW, van der HELM-van MIL AH: Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50: 93-100.
9. JIN J, SMITH FD, STARK C et al.: Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol 2004; 14: 1436-50.
10. YANG X, LEE WH, SOBOTT F et al.: Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc Natl Acad Sci USA 2006; 103: 17237-42.
11. THERY C, OSTROWSKI M, SEGURA E: Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9: 581-93.
12. KILANI RT, MAKSYMOWYCH WP, AITKEN A et al.: Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol 2007; 34: 1650-7.
13. MAKSYMOWYCH WP, NAIDES SL, BYKERK V et al.: Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol 2014 Aug 15 [Epub ahead of print].
14. MAKSYMOWYCH WP, VAN DER HEIJDE D, ALLAART CF et al.: 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther 2014; 16: R99.
15. BOIRE G, CARRIER N, FERNANDES A et al.: 14-3-3η Predicts radiographic progression in recent-onset polyarthritis patients. Ann Rheum Dis 2014; 73 (Suppl. 2).
16. van TUYL LH, BRITSEMMER K, WELLS GA et al.: Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome. Ann Rheum Dis 2012; 71: 33-7.
17. van SCHAARDENBURG D, MAKSYMOWYCH WP, BOERS M, van BEERS-TAS M, MAROTTA A: Serum 14-3-3η predicts the risk of RA development and its higher titres are associated with higher risk. Ann Rheum Dis 2014; 73 (Suppl. 2).
18. van SCHAARDENBURG D, MAKSYMOWYCH WP, BOERS M, TURK S, MAROTTA A: 14-3-3η is an independent predictor of radiographic changes in early RA and higher titres inform a higher likelihood of joint damage progression. Ann Rheum Dis 2014; 73 (Suppl. 2).
19. van SCHAARDENBURG D, MAKSYMOWYCH WP, MAROTTA A: Lower levels of 14-3-3η predict DMARD associated DAS remission at 1 year follow-up. Ann Rheum Dis 2014; 73 (Suppl. 2).
20. SAGAWA A, KANEDA M, GUI Y, MAROTTA A, ARAI J: Evaluation of serum 14-3-3η levels in a Japanese RA cohort treated with tocilizumab. Ann Rheum Dis 2014; 73 (Suppl. 2).
21. MAKSYMOWYCH W, MAROTTA A: Levels of 14-3-3η predict good eular response to anti-TNF treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2014; 73 (Suppl. 2).
22. MAKSYMOWYCH W, van SCHAARDENBURG D, BYKERK V et al.: Antibodies to a novel soluble mediator of inflammation, 14-3-3η, complement existing biomarkers to enhance detection of patients with rheumatoid arthritis. 2014, In preparation.